RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

This recall is currently active, issued January 1, 2025. It was issued by Breckenridge Pharmaceutical, Inc.

Company
Breckenridge Pharmaceutical, Inc
Recall Initiated
December 6, 2024
Posted
January 1, 2025
Recall Number
D-0162-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
76,968 bottles
Firm Location
Berlin, CT, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Distribution

Nationwide in the US

Lot / Code Info

Lot # 230077C, exp. date 11/2025

More recalls by Breckenridge Pharmaceutical, Inc

View all recalls by this company →

Other recent Class II Drug recalls